Cancer News and Research

Latest Cancer News and Research

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2011 fiscal year (ended September 30, 2010).

10 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA").

10 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

Exact Sciences completes underwritten public offering

Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of common stock at a price of $6.00 per share.

10 Nov 2010

Zalicus third quarter total revenue decreases to $1.2 million

"We made solid product development progress this quarter," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "We finalized our development plans for Synavive, and also related to Synavive, we were awarded a Therapeutic Discovery Project grant to help fund Synavive development going forward.

10 Nov 2010

Researchers identify molecular cascade that drives process of reconnection in adult brain after stroke

A stroke wreaks havoc in the brain, destroying its cells and the connections between them. Depending on its severity and location, a stroke can impact someone's life forever, affecting motor activity, speech, memories, and more.

10 Nov 2010

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that a compound identified by the Company as an antagonist of GPR87, an orphan GPCR recently unlocked for drug development by Omeros and linked to squamous cell carcinoma, potentiates the tumor-killing activity of doxorubicin (Adriamycin), a widely used chemotherapeutic agent.

10 Nov 2010

Study finds different DNA alterations in tumor genomes of smokers and never-smokers

Lung tumors in those who smoke and those who never smoked have different DNA alterations in the tumor genomes, according to results of a pilot study presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Study finds no association between working in wafer fabrication cleanrooms, cancer mortality

An exhaustive, five-year epidemiological study conducted by researchers from Vanderbilt University covering more than 100,000 semiconductor industry workers found no association between overall cancer mortality and working in wafer fabrication cleanrooms, the Semiconductor Industry Association reported today.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

EuroNanoMed funds 8 projects with €8 Million for transnational research projects in nanomedicine

EuroNanoMed, a European funding initiative under the ERA-Net scheme of the European Commission aimed at advancing transnational research in Nanomedicine, announced today the projects that will be funded following its 2nd joint transnational call for collaborative research projects. Eight projects, involving 46 partners from 10 countries will be funded with €8 Million provided by EuroNanoMed partners. The research projects were chosen from 33 applications involving 178 applicant groups from 19 EU member and associated states/regions.

10 Nov 2010

Women taking HPV vaccine need only two HPV screening tests for rest of their lives: Research

Women who have had the human papillomavirus vaccine could need only two HPV screening tests for the rest of their lives according to new calculations being presented at the NCRI Cancer Conference in Liverpool.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Idera Pharmaceuticals, Inc. today announced two presentations of preclinical data from its autoimmune and inflammatory disease program at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Atlanta, Georgia. One presentation is entitled "IMO-3100, a Toll-like Receptor (TLR) Antagonist, Suppresses TLR7- and TLR9-mediated Immune Responses in Non-human Primates" (#856).

10 Nov 2010

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

UCB and U.S. based partner Immunomedics Inc. announced that results from the phase IIB study, EMBLEM, showed that certain doses of epratuzumab were associated with a meaningful and statistically significant reduction in disease activity in adult patients with moderate to severe active SLE.

10 Nov 2010

Medicinal mushroom formula fights breast cancer

Researchers at Indiana University and Methodist Research Institute studied an innovative medicinal mushroom formula against breast cancer. The impressive results are found in the December issue of the International Journal of Oncology. Lead investigator Dr. Daniel Sliva says, "The formula inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells."

10 Nov 2010

Researcher awarded Sylvia and Charles Viertel Charitable Foundation Fellowship

Walter and Eliza Hall Institute researcher Dr Ross Dickins has been awarded a Sylvia and Charles Viertel Charitable Foundation Fellowship worth $AUD975,000 over five years.

10 Nov 2010

Breast cancer patients more likely to have joint pain from taking AIs: Study

Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.

10 Nov 2010

Cancer News and Research

Latest Cancer News and Research

Bioniche Life Sciences announces first quarter fiscal 2011 results

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Exact Sciences completes underwritten public offering

Zalicus third quarter total revenue decreases to $1.2 million

Researchers identify molecular cascade that drives process of reconnection in adult brain after stroke

Omeros identifies orphan GPCR compound that potentiates tumor-killing activity of doxorubicin

Study finds different DNA alterations in tumor genomes of smokers and never-smokers

Study finds no association between working in wafer fabrication cleanrooms, cancer mortality

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

EuroNanoMed funds 8 projects with €8 Million for transnational research projects in nanomedicine

Women taking HPV vaccine need only two HPV screening tests for rest of their lives: Research

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Preclinical data from Idera's autoimmune and inflammatory disease program presented at 74th ACR

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Medicinal mushroom formula fights breast cancer

Researcher awarded Sylvia and Charles Viertel Charitable Foundation Fellowship

Breast cancer patients more likely to have joint pain from taking AIs: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in